| Body na spoluautora | Body za publikaci pro MU | Odkaz ISVaV | | 4,33 | 30,31 | Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis
|
| 2,11 | 4,21 | Spondylotic cervical myelopathy: what is the best approach to treatment?
|
| 2,40 | 7,20 | Krční myelopatie - diagnostický problém
|
| 0,00 | 0,00 | The natural course of pre-clinical spondylotic cervical cord compression and predictors of its clinical manifestation
|
| 1,87 | 5,62 | Mitoxantrone therapy in rapidly worsening multiple sclerosis
|
| 5,71 | 34,27 | Predictive factors for spondylotic cervical myelopathy treated conservatively or surgically
|
| 34,27 | 34,27 | Cross- sectional transverse area and hyperintensities on MRI in spondylotic cervical myelopathy
|
| 2,77 | 19,41 | Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis
|
| 3,25 | 22,76 | Presymptomatic spondylotic cervical myelopathy. An updated predictive model
|
| 17,86 | 71,45 | Cross-sectional transverse area and hyperintensities on magnetic resonance imaging in relation to the clinical picture in cervical spondylotic myelopathy
|
| 1,40 | 14,04 | Akutní stavy v geriatrii
|
| 0,00 | 0,00 | Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes polymorphisms in multiple sclerosis.
|
| 8,75 | 52,48 | Matrix metalloproteinase-9 gene polymorphisms in multiple sclerosis
|
| 0,00 | 0,00 | Some pharmacogenetic aspects of DNA variability in proinflammatory genes (TNF alpha and beta) in patients with multiple sclerosis
|
Back
(c) Michal Bulant, 2011